The Orange Oakleaf Butterfly is similar to its surroundings with detail that sets it apart.
CIMERLI™ is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection). Discover the comprehensive support and savings of CIMERLI Solutions™ and learn more about CIMERLI™.
Explore CIMERLI™Developing immuno-oncology therapies for patients in need
The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.
We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.
About Coherus Immuno-oncology
